SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Instagram Outage Disrupts Thousands of U.S. Users 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CAMBRIDGE, Mass., Jan. 11, 2018 -- Manus Bio Inc. (Manus Bio), a company which produces complex natural products through advanced fermentation, announced today that it has received funding from the Bill & Melinda Gates Foundation for the development of a scalable and cost-effective production method for artemisinin, a key therapeutic for treating malaria. Manus Bio will use its proprietary microbial chassis and unique enzyme engineering approaches to develop an advanced fermentation process for low-cost manufacturing of artemisinin.
"Malaria remains one of the largest health problems in the world today which, despite great progress in recent years, still kills over 600,000 people in a given year. Artemisinin combination therapies are recommended by the World Health Organization as first line treatment of malaria, but the vast majority of artemisinin produced today is derived from plants. With the support of the Bill & Melinda Gates Foundation, we are deploying our fermentation technology to lower the cost of artemisinin, create a stable supply, and expand its use," said Dr. Ajikumar Parayil, CEO of Manus Bio.
About Artemisinin
Artemisinin was the subject of the 2015 Nobel Prize in Medicine awarded to Tu Youyou based on her work in identifying the molecule as a potential treatment for malaria. Tu researched Traditional Chinese Medicine which led her to identify an extract from the plant Artemisia annua (sweet wormwood) as a treatment for malaria.
About Manus Bio
Manus Bio is a global leader in the use of advanced fermentation technology for manufacturing complex, bioactive natural products as flavors, fragrances, food ingredients, biopesticides, and pharmaceuticals. The core team and technology are from the Massachusetts Institute of Technology (MIT), and the company is headquartered in Cambridge, MA, USA. For more information, visit www.manusbio.com.
Contact: [email protected]
